A fresh $4.8M seed round is set to fuel Primogene GmbH's biotechnology efforts in Leipzig, Germany. The company, which specializes in developing bioprocesses to manufacture functional ingredients based on multi-enzyme systems, announced the new capital will advance its work in creating components for nutrition, personal care, and pharmaceutical raw materials.
High-Tech Gründerfonds (HTGF) anchored the investment. This funding round is also notably co-financed by the European Union and from tax revenues based on the budget adopted by the Saxon State Parliament, underscoring a broader public interest in Primogene's innovative approach.















